PODD Quote, Financials, Valuation and Earnings

iRhythm Technologies has a net margin of 16.85% compared to Insulet's net margin of -0.81%. Insulet's return on equity of 43.11% beat iRhythm Technologies's return on equity of -100.75%.

Insulet has a consensus price target of $312.27, signalling upside risk potential of 19.78%. On the other hand iRhythm Technologies has an analysts' consensus of $130.92 which suggests that it could grow by 23.52%. Given that iRhythm Technologies has higher upside potential than Insulet, analysts believe iRhythm Technologies is more attractive than Insulet.

Insulet has a beta of 1.300, which suggesting that the stock is 30.008% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.450, suggesting its more volatile than the S&P 500 by 44.979%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $597.5M, which are larger than iRhythm Technologies quarterly revenues of $164.3M. Insulet's net income of $100.7M is higher than iRhythm Technologies's net income of -$1.3M. Notably, Insulet's price-to-earnings ratio is 45.03x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 9.30x versus 5.59x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 16.85% compared to Insulet's net margin of 30.99%. Insulet's return on equity of 43.11% beat Intuitive Surgical's return on equity of 15.82%.

Insulet has a consensus price target of $312.27, signalling upside risk potential of 19.78%. On the other hand Intuitive Surgical has an analysts' consensus of $576.03 which suggests that it could grow by 11.94%. Given that Insulet has higher upside potential than Intuitive Surgical, analysts believe Insulet is more attractive than Intuitive Surgical.

Insulet has a beta of 1.300, which suggesting that the stock is 30.008% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.555, suggesting its more volatile than the S&P 500 by 55.506%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $597.5M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Insulet's net income of $100.7M is lower than Intuitive Surgical's net income of $698.4M. Notably, Insulet's price-to-earnings ratio is 45.03x while Intuitive Surgical's PE ratio is 75.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 9.30x versus 21.44x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 16.85% compared to Insulet's net margin of -58.2%. Insulet's return on equity of 43.11% beat Masimo's return on equity of -23.05%.

Insulet has a consensus price target of $312.27, signalling upside risk potential of 19.78%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 19.52%. Given that Insulet has higher upside potential than Masimo, analysts believe Insulet is more attractive than Masimo.

Insulet has a beta of 1.300, which suggesting that the stock is 30.008% more volatile than S&P 500. In comparison Masimo has a beta of 1.278, suggesting its more volatile than the S&P 500 by 27.807%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $597.5M, which are smaller than Masimo quarterly revenues of $600.7M. Insulet's net income of $100.7M is higher than Masimo's net income of -$349.6M. Notably, Insulet's price-to-earnings ratio is 45.03x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 9.30x versus 4.23x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 16.85% compared to Insulet's net margin of 0.27%. Insulet's return on equity of 43.11% beat Tandem Diabetes Care's return on equity of -37.18%.

Insulet has a consensus price target of $312.27, signalling upside risk potential of 19.78%. On the other hand Tandem Diabetes Care has an analysts' consensus of $38.24 which suggests that it could grow by 111.73%. Given that Tandem Diabetes Care has higher upside potential than Insulet, analysts believe Tandem Diabetes Care is more attractive than Insulet.

Insulet has a beta of 1.300, which suggesting that the stock is 30.008% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.525, suggesting its more volatile than the S&P 500 by 52.461%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $597.5M, which are larger than Tandem Diabetes Care quarterly revenues of $282.6M. Insulet's net income of $100.7M is higher than Tandem Diabetes Care's net income of $755K. Notably, Insulet's price-to-earnings ratio is 45.03x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 9.30x versus 1.26x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.